The role of surgical management in recurrent thymic tumors

Masatsugu Hamaji, Mark S. Allen, Stephen D. Cassivi, Francis C. Nichols, Dennis A Wigle, Claude Deschamps, K. Robert Shen

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: There are few data on outcomes after surgical treatment for recurrent thymic tumors. The aim of this study is to analyze and compare long-term outcomes of treatments for recurrent thymic tumors. Methods: Between January 1956 and December 2009, 344 thymic tumors were surgically resected (309 thymomas, 22 thymic carcinomas, 12 thymic carcinoids, and 1 thymolipoma). There were 48 recurrences (13.9%): 30 thymomas, 9 thymic carcinomas, and 9 thymic carcinoids. There were 27 men and 21 women with a median age of 51 years (range, 27 to 83). Retrospective chart review was performed. Relevant factors for recurrence as well as survival and progression-free interval were analyzed. Results: The median follow-up interval from the initial operation was 83 months (range, 9 to 515). Recurrence adversely affected overall survival in surgically resected thymic tumors (p = 0.0014). In multivariate analysis, the initial Masaoka stage, incomplete resection, and World Health Organization histology were significant risk factors for recurrence. In multivariate analysis, only surgical management was associated with prolonged survival p = 0.0038) and improved progression-free interval (p = 0.0378) in recurrent thymoma. Five-year survival after recurrent thymoma was 54%. For recurrent thymic carcinoma, surgery did not improve survival. For these patients, chemotherapy was associated with improved progression-free interval after recurrence (p = 0.0295). There were no 5-year survivors of recurrent thymic carcinoma. Conclusions: Our data suggest that surgical management is associated with better outcome and is the treatment of choice for recurrent thymoma. For recurrent thymic carcinoma, surgical management has a very limited role, and chemotherapy appears to be a more effective treatment modality.

Original languageEnglish (US)
Pages (from-to)247-254
Number of pages8
JournalAnnals of Thoracic Surgery
Volume94
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Thymus Neoplasms
Thymoma
Recurrence
Survival
Carcinoid Tumor
Multivariate Analysis
Drug Therapy
Disease-Free Survival
Survivors
Histology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Hamaji, M., Allen, M. S., Cassivi, S. D., Nichols, F. C., Wigle, D. A., Deschamps, C., & Shen, K. R. (2012). The role of surgical management in recurrent thymic tumors. Annals of Thoracic Surgery, 94(1), 247-254. https://doi.org/10.1016/j.athoracsur.2012.02.092

The role of surgical management in recurrent thymic tumors. / Hamaji, Masatsugu; Allen, Mark S.; Cassivi, Stephen D.; Nichols, Francis C.; Wigle, Dennis A; Deschamps, Claude; Shen, K. Robert.

In: Annals of Thoracic Surgery, Vol. 94, No. 1, 07.2012, p. 247-254.

Research output: Contribution to journalArticle

Hamaji, M, Allen, MS, Cassivi, SD, Nichols, FC, Wigle, DA, Deschamps, C & Shen, KR 2012, 'The role of surgical management in recurrent thymic tumors', Annals of Thoracic Surgery, vol. 94, no. 1, pp. 247-254. https://doi.org/10.1016/j.athoracsur.2012.02.092
Hamaji, Masatsugu ; Allen, Mark S. ; Cassivi, Stephen D. ; Nichols, Francis C. ; Wigle, Dennis A ; Deschamps, Claude ; Shen, K. Robert. / The role of surgical management in recurrent thymic tumors. In: Annals of Thoracic Surgery. 2012 ; Vol. 94, No. 1. pp. 247-254.
@article{577ce19c1a314216a1e795f35d96f24e,
title = "The role of surgical management in recurrent thymic tumors",
abstract = "Background: There are few data on outcomes after surgical treatment for recurrent thymic tumors. The aim of this study is to analyze and compare long-term outcomes of treatments for recurrent thymic tumors. Methods: Between January 1956 and December 2009, 344 thymic tumors were surgically resected (309 thymomas, 22 thymic carcinomas, 12 thymic carcinoids, and 1 thymolipoma). There were 48 recurrences (13.9{\%}): 30 thymomas, 9 thymic carcinomas, and 9 thymic carcinoids. There were 27 men and 21 women with a median age of 51 years (range, 27 to 83). Retrospective chart review was performed. Relevant factors for recurrence as well as survival and progression-free interval were analyzed. Results: The median follow-up interval from the initial operation was 83 months (range, 9 to 515). Recurrence adversely affected overall survival in surgically resected thymic tumors (p = 0.0014). In multivariate analysis, the initial Masaoka stage, incomplete resection, and World Health Organization histology were significant risk factors for recurrence. In multivariate analysis, only surgical management was associated with prolonged survival p = 0.0038) and improved progression-free interval (p = 0.0378) in recurrent thymoma. Five-year survival after recurrent thymoma was 54{\%}. For recurrent thymic carcinoma, surgery did not improve survival. For these patients, chemotherapy was associated with improved progression-free interval after recurrence (p = 0.0295). There were no 5-year survivors of recurrent thymic carcinoma. Conclusions: Our data suggest that surgical management is associated with better outcome and is the treatment of choice for recurrent thymoma. For recurrent thymic carcinoma, surgical management has a very limited role, and chemotherapy appears to be a more effective treatment modality.",
author = "Masatsugu Hamaji and Allen, {Mark S.} and Cassivi, {Stephen D.} and Nichols, {Francis C.} and Wigle, {Dennis A} and Claude Deschamps and Shen, {K. Robert}",
year = "2012",
month = "7",
doi = "10.1016/j.athoracsur.2012.02.092",
language = "English (US)",
volume = "94",
pages = "247--254",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - The role of surgical management in recurrent thymic tumors

AU - Hamaji, Masatsugu

AU - Allen, Mark S.

AU - Cassivi, Stephen D.

AU - Nichols, Francis C.

AU - Wigle, Dennis A

AU - Deschamps, Claude

AU - Shen, K. Robert

PY - 2012/7

Y1 - 2012/7

N2 - Background: There are few data on outcomes after surgical treatment for recurrent thymic tumors. The aim of this study is to analyze and compare long-term outcomes of treatments for recurrent thymic tumors. Methods: Between January 1956 and December 2009, 344 thymic tumors were surgically resected (309 thymomas, 22 thymic carcinomas, 12 thymic carcinoids, and 1 thymolipoma). There were 48 recurrences (13.9%): 30 thymomas, 9 thymic carcinomas, and 9 thymic carcinoids. There were 27 men and 21 women with a median age of 51 years (range, 27 to 83). Retrospective chart review was performed. Relevant factors for recurrence as well as survival and progression-free interval were analyzed. Results: The median follow-up interval from the initial operation was 83 months (range, 9 to 515). Recurrence adversely affected overall survival in surgically resected thymic tumors (p = 0.0014). In multivariate analysis, the initial Masaoka stage, incomplete resection, and World Health Organization histology were significant risk factors for recurrence. In multivariate analysis, only surgical management was associated with prolonged survival p = 0.0038) and improved progression-free interval (p = 0.0378) in recurrent thymoma. Five-year survival after recurrent thymoma was 54%. For recurrent thymic carcinoma, surgery did not improve survival. For these patients, chemotherapy was associated with improved progression-free interval after recurrence (p = 0.0295). There were no 5-year survivors of recurrent thymic carcinoma. Conclusions: Our data suggest that surgical management is associated with better outcome and is the treatment of choice for recurrent thymoma. For recurrent thymic carcinoma, surgical management has a very limited role, and chemotherapy appears to be a more effective treatment modality.

AB - Background: There are few data on outcomes after surgical treatment for recurrent thymic tumors. The aim of this study is to analyze and compare long-term outcomes of treatments for recurrent thymic tumors. Methods: Between January 1956 and December 2009, 344 thymic tumors were surgically resected (309 thymomas, 22 thymic carcinomas, 12 thymic carcinoids, and 1 thymolipoma). There were 48 recurrences (13.9%): 30 thymomas, 9 thymic carcinomas, and 9 thymic carcinoids. There were 27 men and 21 women with a median age of 51 years (range, 27 to 83). Retrospective chart review was performed. Relevant factors for recurrence as well as survival and progression-free interval were analyzed. Results: The median follow-up interval from the initial operation was 83 months (range, 9 to 515). Recurrence adversely affected overall survival in surgically resected thymic tumors (p = 0.0014). In multivariate analysis, the initial Masaoka stage, incomplete resection, and World Health Organization histology were significant risk factors for recurrence. In multivariate analysis, only surgical management was associated with prolonged survival p = 0.0038) and improved progression-free interval (p = 0.0378) in recurrent thymoma. Five-year survival after recurrent thymoma was 54%. For recurrent thymic carcinoma, surgery did not improve survival. For these patients, chemotherapy was associated with improved progression-free interval after recurrence (p = 0.0295). There were no 5-year survivors of recurrent thymic carcinoma. Conclusions: Our data suggest that surgical management is associated with better outcome and is the treatment of choice for recurrent thymoma. For recurrent thymic carcinoma, surgical management has a very limited role, and chemotherapy appears to be a more effective treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=84862906979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862906979&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2012.02.092

DO - 10.1016/j.athoracsur.2012.02.092

M3 - Article

C2 - 22632880

AN - SCOPUS:84862906979

VL - 94

SP - 247

EP - 254

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -